Please support the Valley News during the COVID-19 pandemic

The COVID-19 pandemic has brought the local economy — and many of the advertisers who support our work — to a near standstill. During this unprecedented challenge, we continue to make our coronavirus coverage free to everyone at because we feel our most critical mission is to deliver vital information to our communities.

If you believe local news is essential, especially during this crisis, we are asking for your support. Please consider subscribing or making a donation today. Learn more at the links below.

Thank you for your support of the Valley News.

Dan McClory, publisher

DHMC part of trial for COVID-19 pneumonia treatment

Published: 5/20/2020 6:07:11 PM
Modified: 5/20/2020 6:07:03 PM

LEBANON — Researchers at Dartmouth-Hitchcock Medical Center are participating in a new “phase 3” study approved by the Food and Drug Administration to determine whether a drug known as lenzilumab can be used to treat patients hospitalized with pneumonia because of COVID-19.

DHMC will help assess whether lenzilumab, a monoclonal antibody developed by the California-based biopharmaceutical company Humanigen, prevents COVID-19-associated pneumonia from progressing to respiratory failure or death, Dartmouth-Hitchcock said in a news release on Wednesday.

A total of 238 patients at medical centers around the country, including DHMC, will receive either lenzilumab or a placebo to see if it works, alongside standard care practices to “alleviate the immune-mediated Cytokine Release Syndrome,” thereby reducing the need for invasive ventilators for COVID-19 pneumonia patients, the release said.

The study will be directed toward patients who have biomarkers indicating that they are at high risk for their COVID-19 pneumonia to get worse.

Valley News

24 Interchange Drive
West Lebanon, NH 03784


© 2019 Valley News
Terms & Conditions - Privacy Policy